Avenue THERAPEUTICS, Inc. (ATXI) intrinsic value & 10-year financials
Avenue THERAPEUTICS, Inc. (ATXI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $1.4M, with an average return on invested capital of -521.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.43
- Market cap
- $939.6K
- Revenue (FY2025)
- $1.4M
- ROIC (10-yr avg)
- -521.8%
- Free cash flow (FY2025)
- —
ATXI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.4M | -$2.9M | — | — | -219.6% | -133.2% |
| FY2024 | $0 | -$11.7M | — | — | — | -515.3% |
| FY2023 | — | -$10.5M | — | — | — | -530.0% |
| FY2022 | — | -$3.6M | — | — | — | -218.7% |
| FY2021 | — | -$3.7M | -$0.22 | — | — | -128.4% |
| FY2020 | — | -$5.2M | -$0.31 | — | — | -112.5% |
| FY2019 | — | -$25.9M | — | — | — | -839.9% |
| FY2018 | — | -$21.5M | — | — | — | -283.6% |
| FY2017 | — | -$12.3M | — | — | — | -2504.2% |
| FY2016 | — | -$3.2M | — | — | — | 48.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
AVENUE THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
AVENUE THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just 6.7% ROIC.
AVENUE THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
AVENUE THERAPEUTICS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.